Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: A meta-analysis

Colorectal Disease

Volumn 12, Issue 7, 2010, Pages 615-623

  Zhao, G ^a,b   Gao, P ^a,b   Yang, K H ^a   Tian, J H ^a   Ma, B ^a  

^a LANZHOU UNIVERSITY   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

Author keywords

Capecitabine; Chemotherapy; Colorectal neoplasms; Fluorouracil; Meta analysis; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFECT; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; META ANALYSIS; METASTASIS; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; PRODRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77958129436     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2009.01879.x     Document Type: Article

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
2. U.S. Cancer Statistics Working Group. (2007) United States Cancer Statistics: 2004 Incidence and Mortality. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, Atlanta (GA).
3. Cancer research UK. Cancer Statistics. Available at http://www.cancerresearchuk.org/ (accessed 1 October 2008)..
4. Isacoff WH, Borud K. Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. World J Surg 1997; 21: 748-62.
5. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol) 1997; 9: 248-51.
6. Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-75.
7. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34: 1274-81.
8. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-7.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
10. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004; 90: 1190-7.
11. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
12. Rischin D, White MA, Matthews JP et al. A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis. Med J Aust 2000; 173: 125-7.
13. Wilson A, Wynn A, Parker H. Patient and carer satisfaction with 'hospital at home': quantitative and qualitative results from a randomised controlled trial. Br J Gen Pract 2002; 52: 9-13.
14. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU / LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122-9.
15. Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604.
16. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-23.
17. Rothenberg ML, Cox JV, Butts M et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil / folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19: 1720-6.
18. Comella P, Massidda B, Filippelli G et al. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil / leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol 2009; 135: 217-26.
19. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil / folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-12.
20. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 2008; 26: 3523-9.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
22. Higgins JPT, Green S, eds. (2006) Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Library Issue 4. John Wiley, Chichester.
23. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 341-50.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
25. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 15: 629-34.
26. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
27. Arkenau HT, Graeven U, Kubicka S et al. Oxaliplatin in combination with 5-fluorouracil / leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7: 60-4.
28. Díaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-30.
29. Martoni AA, Pinto C, Fabio FD et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 2006; 42: 3161-8.
30. Hebber M, Bennouna J, Boige V. Safety and quality of life (QoL) findings from a randomized phase III study of capecitabine+oxaliplatin (XELOX) vs. infusional 5-FU / folinic acid (FA)+oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25(18 suppl): 188s. (Abstract 4099).
31. Shi B, Zhang XB, Xu J. Capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin in metastatic colorectal cancer. J Prac Oncol 2007; 21: 525-6.
32. Jiang GB, Xu D, Cao FL, Cai JM. Capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer. J Jiangxi Med 2006; 41: 387-9.
33. Zhang JW, Miao JH, Zhao F, Chen SB, Guo XD. Analysis of effects of the combination of capecitabine and oxaliplatin as first-line chemotherapy on metastatic colorectal cancer. Mod Med J 2008; 36: 37-9.
34. Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil / leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910-7.